Editas Medicine Inc (NASDAQ:EDIT) has a beta value of 2.05 and has seen 2.32 million shares traded in the last trading session. The company, currently valued at $631.57M, closed the last trade at $7.72 per share which meant it lost -$0.41 on the day or -5.04% during that session. The EDIT stock price is -54.27% off its 52-week high price of $11.91 and 21.24% above the 52-week low of $6.08. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.33 million shares traded. The 3-month trading volume is 1.86 million shares.

Editas Medicine Inc (NASDAQ:EDIT) trade information

Sporting -5.04% in the red in last session, the stock has traded in the red over the last five days, when the EDIT stock price touched $7.72 or saw a rise of 14.98%. Year-to-date, Editas Medicine Inc shares have moved -23.79%, while the 5-day performance has seen it change -14.22%. Over the past 30 days, the shares of Editas Medicine Inc (NASDAQ:EDIT) have changed -7.10%. Short interest in the company has seen 13.52 million shares shorted with days to cover at 6.88.

Editas Medicine Inc (EDIT) estimates and forecasts

Figures show that Editas Medicine Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -7.99% over the past 6 months, with this year growth rate of -31.68%, compared to 13.60% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 5.60% and -19.60% for the next quarter. Revenue growth from the last financial year stood is estimated to be -54.40%.

12 analysts offering their estimates for the company have set an average revenue estimate of $7.9 million for the current quarter. 12 have an estimated revenue figure of $6 million for the next quarter concluding in Jun 2024. Year-ago sales stood $9.85 million and $4.17 million respectively for this quarter and the next, and analysts expect sales will shrink by -19.80% for the current quarter and 43.90% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 2.88% over the past 5 years. Earnings growth for 2024 is a modest -26.46% while over the next 5 years, the company’s earnings are expected to increase by 1.70%.

EDIT Dividends

Editas Medicine Inc is expected to release its next earnings report between May 03 and May 07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Editas Medicine Inc (NASDAQ:EDIT)’s Major holders

Insiders own 0.91% of the company shares, while shares held by institutions stand at 75.57% with a share float percentage of 76.26%. Investors are also buoyed by the number of investors in a company, with Editas Medicine Inc having a total of 310 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc with over 8.17 million shares worth more than $67.2 million. As of Jun 29, 2023, Vanguard Group Inc held 10.00% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 7.6 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $62.51 million and represent 9.30% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Aug 30, 2023, the former fund manager holds about 5.94% shares in the company for having 4.85 million shares of worth $43.18 million while later fund manager owns 2.49 million shares of worth $20.51 million as of Jun 29, 2023, which makes it owner of about 3.05% of company’s outstanding stock.